BioCentury
ARTICLE | Distillery Therapeutics

Cancer

April 3, 2018 6:33 PM UTC

Mouse studies suggest antibodies against the conserved α3 domain of MICA and MICB could help treat metastatic melanoma and colorectal cancer. In mouse models of metastatic melanoma and colon cancer, a mAb targeting the MICA α3 domain decreased lung metastases compared with an isotype control antibody. In a second mouse model of MICA- and MICB-expressing melanoma, the mAb decreased tumor size. In a xenograft mouse model of metastatic melanoma, the mAb plus adoptive transfer of human NK cells decreased lung and liver metastases and increased survival. Next steps include testing mAbs targeting the MICA and MICB α3 domains in combination with other therapies in animal models of melanoma and multiple myeloma (MM).

CanCure LLC has CuraB-10 and CuraB-20, antibodies targeting both soluble MICA and MICB, in preclinical testing for cancer...